e-learning
resources
Stockholm 2007
Monday 17.09.2007
Diagnostic markers and therapy in hospital-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Predictive value of procalcitonin in ventilator-associated pneumonia
R. Seligman, B. GS Seligman, P. T. Barcellos, M. S. Duncan, P. J. Z. Teixeira (Porto Alegre, Novo Hamburgo, Brazil)
Source:
Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Session:
Diagnostic markers and therapy in hospital-acquired pneumonia
Session type:
Thematic Poster Session
Number:
2406
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Seligman, B. GS Seligman, P. T. Barcellos, M. S. Duncan, P. J. Z. Teixeira (Porto Alegre, Novo Hamburgo, Brazil). Predictive value of procalcitonin in ventilator-associated pneumonia. Eur Respir J 2007; 30: Suppl. 51, 2406
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia
Source: Eur Respir J 2008; 31: 356-362
Year: 2008
Specific treatment failure of the ventilator-associated pneumonia (VAP): predictive values
Source: Eur Respir J 2006; 28: Suppl. 50, 786s
Year: 2006
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study
Source: Eur Respir J 2009; 34: 1364-1375
Year: 2009
Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
MR-proANP and prognosis of ventilator-associated pneumonia
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
Comparision of procalcitonin and CURB-65 in pneumonia
Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Year: 2012
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Copeptin and prognosis of ventilator-associated pneumonia
Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens
Year: 2008
Prognostic value of procalcitonin in community-acquired pneumonia
Source: Eur Respir J 2011; 37: 384
Year: 2011
Comparison of biomarkers and SOFA score prognostic value in ventilator-associated pneumonia
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009
Procalcitonin has wider applicability in community-acquired pneumonia than other biomarkers
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Serum procalcitonin and community-acquired pneumonia in childhood
Source: Eur Respir J 2005; 26: Suppl. 49, 167s
Year: 2005
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia
Source: Eur Respir J 2010; 35: 805-811
Year: 2010
Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients
Source: Eur Respir J 2004; 24: Suppl. 48, 188s
Year: 2004
Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
C-reactive protein in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
Source: Eur Respir J 2016; 48: 797-807
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept